Key TAPS Production Advantages Include:
Significant Reduction in Cost of Goods (COGS) & Process Mass Intensity (PMI)
- ~50% reduction in the amount of excess amino acids and coupling reagents used
- >90% reduction in organic solvent waste
- “Green” solvents used compared to DMF in SPPS
- “Green” amine replaces non-eco-friendly piperidine
- Lower waste disposal costs
- Less impurities and typically higher yields
Technical Advantages
- Improved reaction rates
- Reduced or eliminated aggregation in aggregation-prone peptides
- For most peptides, the SPPS route of synthesis can be maintained with the same or similar impurity profile
- Suitable for fragment approaches, including coupling large fragments to peptides on the Tag
- Pre-purification of the protected peptide possible
- Uses standard chemical reactors and filtration equipment
- PAT and in-line-monitoring directly applicable
TAPS Phase Separation Stage
TAPS empowers peptide-based drug development with automation potential, flexible synthesis strategies, and compatibility with existing peptide chemistry. Proven on high-value APIs like GLP-1 analogues, our customers benefit from unmatched efficiency, sustainability, and cost savings. TAPS is not just an incremental improvement, but a paradigm shift for CDMOs and pharma innovators ready to future-proof their peptide production.
CordenPharma is pleased to announce we won a CPHI 2025 Pharma Award for API Development & Innovation with our TAPS technology. Below, Dr. Mimoun Ayoub, Global Head of Peptides & Oligonucleotides Platforms, is joined by our CordenPharma Frankfurt peptide development team to accept the award on 28 October 2025.
Listen to Dr. Mimoun Ayoub present this innovative TAPS technology at Tides US 2025 in San Diego.
Integrated Supply for TAPS
For peptide-based therapeutics, CordenPharma excels with unique end-to-end solutions across our global facility network for the supply of small-, mid- and large-scale peptide drug substance seamlessly integrated with oral solid dosage formulations and robust sterile injectable fill and finish manufacturing.
Want to find out more?
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.